 - 61 patients with NRG1 cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date- Encouraging early clinical activity observed, with confirmed responses in 5 of 12 patients with pancreatic cancer 42 and in 13 of 45 patients across several NRG1 tumor types 29- Zenocutuzumab continues to be well tolerated with a favorable safety profile- Company to host investor call to discuss interim clinical results and provide a program update on Sunday, June 6 at 6:00 PM ET 